Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-03-15
2011-03-15
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07906483
ABSTRACT:
Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.
REFERENCES:
patent: 5686409 (1997-11-01), McFadden et al.
patent: 5688824 (1997-11-01), Williams
patent: 5917014 (1999-06-01), McFadden et al.
patent: 5939525 (1999-08-01), McFadden et al.
patent: 7285530 (2007-10-01), Lucas et al.
patent: 7514405 (2009-04-01), Lucas et al.
patent: 2004/0029801 (2004-02-01), Zhong et al.
patent: 0356945 (1993-11-01), None
patent: 0567816 (1993-11-01), None
patent: 0985412 (2000-03-01), None
patent: 1365798 (2002-04-01), None
patent: 0817646 (2003-01-01), None
patent: 1223971 (2005-06-01), None
patent: H2-108633 (1990-04-01), None
patent: H6-9425 (1994-01-01), None
patent: WO 91/15221 (1991-10-01), None
patent: WO 92/06706 (1992-04-01), None
patent: WO 92/22320 (1992-12-01), None
patent: WO 93/10812 (1993-06-01), None
patent: WO 95/27503 (1995-10-01), None
patent: WO 96/30042 (1996-10-01), None
patent: WO 97/10006 (1997-03-01), None
patent: WO 99/62540 (1999-12-01), None
patent: WO 00/45834 (2000-08-01), None
patent: WO 00/53793 (2000-09-01), None
patent: WO 01/30379 (2001-05-01), None
patent: WO 01/38790 (2001-05-01), None
patent: WO 01/039790 (2001-06-01), None
patent: WO 02/026245 (2002-04-01), None
patent: WO 2004/039391 (2004-05-01), None
Aziz et al., “Transplant Arterial Vasculopathy: Evidence for a Dual Pattern of Endothelial Injury and the Source of Smooth Muscle Cells in Lesions of Intimal Hyperplasia,”J. Heart Lung Transplant. 14:S123-S136, 1995.
Abraham et al., “β4-Integrins Mediate Antigen-Induced Late Bronchial Responses and Prolonged Airway Hyperresponsiveness in Sheep,”J. Clin. Invest. 93:776-787, 1994.
Abraham et al., “Characterization of a Late Phase Pulmonary Response after Antigen Challenge in Allergic Sheep,”Am. Rev. Respir. Dis. 128:839-844, 1993.
Barsoum, “Introduction of Stable High-Copy-Number DNA into Chinese Hamster Ovary Cells by Electroporation,”DNA Cell. Biol. 9:293-300, 1990.
Bédard et al., “Prevention of Chronic Renal Allograft Rejection by SERP-1 Protein,”Transplantation81:908-914, 2006.
Ben-Nun et al., “The Rapid Isolation of Clonable Antigen-Specific T Lymphocyte Lines Capable of Mediating Autoimmune Encephalomyelitis,”Eur. J. Immunol. 11:195-199, 1981.
Bowes et al., “Diaspirin Cross-Linked Hemoglobin Improves Neurological Outcome Following Reversible but not Irreversible CNS Ischemia in Rabbits,”Stroke25:2253-2257, 1994.
Burgess et al., “Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-Binding Activities by Site-Directed Mutagenesis of a Single Lysine Residue”J. Cell Biol. 111:2129-2138, 1990.
Burkly et al., “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigen-4 Integrin,”Diabetes43:529-534, 1994.
Colvin, “CADI,Canti, Cavi,” Transplantation83:677-678, 2007.
Cosimi et al., “In Vivo Effects of Monoclonal Antibody to ICAM-1 (CD54) in Nonhuman Primates with Renal Allografts,”J. Immunol. 144:4604-4612, 1990.
Dai et al., “Serp-1, a Viral Anti-Inflammatory Serpin, Regulates Cellular Serine Proteinase and Serpin Responses to Vascular Injury,”J. Biol. Chem. 278:18563-18572, 2003.
Davis et al., “The Effect of Age on Cerebral Oedema, Cerebral Infarction and Neuroprotective Potential in Experimental Occlusive Stroke,”Acta Neurochir. Suppl. 60:282-284, 1994.
Davison and Moss, “New Vaccinia Virus Recombination Plasmids Incorporating a Synthetic Late Promoter for High Level Expression of Foreign Proteins,”Nucl. Acids Res. 18:4285-4286, 1990.
Doerschuk et al., “CD18-Dependent and -Independent Mechanisms of Neutrophil Emigration in the Pulmonary and Systemic Microcirculation of Rabbits,”J. Immunol. 144:2327-2333, 1990.
Fava et al., “Transforming Growth Factor α1 (TGF- α1) Induced Neutrophil Recruitment to Synovial Tissues: Implications for TGF- α-Driven Synovial Inflammation and Hyperplasia,”J. Exp. Med. 173:1121-1132, 1991.
Friedrichs et al., “Effects of Heparin and N-Acetyl Heparin on Ischemia/Reperfusion-Induced Alterations in Myocardial Function in the Rabbit Isolated Heart,”Circulation Res. 75:701-710, 1994.
Fritz, “Proteinase Inhibitors in Severe Inflammatory Processes (Septic Shock and Experimental Endotoxaemia): Biochemical, Pathophysiological and Therapeutic Aspects,” inProtein Degradation in Health and Disease, Ciba Foundation Symposium 75:351-379, 1980.
Fryer et al., “Influence of Macrophage Depletion on Bacterial Translocation and Rejection in Small Bowel Transplantation,”Transplantation62:553-559, 1996.
Gilhar and Elzioni, “The Nude Mouse Model for the Study of Human Skin Disorders,”Dermatology189:5-8, 1994.
Gooding et al., “Virus Proteins that Counteract Host Immune Defenses”Cell71:5-7, 1992.
Gown et al., “Human Atherosclerosis- Immunocytochemical Analysis of the Cellular Composition of Human Atherosclerotic Lesions,”Am. J. Physiol. 125:191-207, 1986.
Haber, “Can a Viral Serine Proteinase Inhibitor Prevent Postangioplasty Restenosis?”Circulation94:2694-2695, 1996.
Hagerty and Allen, “Tolerance to Self and the Processing and Presentation of Self Antigens,”Intern. Rev. Immunol. 10:313-319, 1993.
Hammer et al., “Spontaneous Inflammatory Disease in Transgenic Rates Expressing HLA-B27 and Human β2m: An Animal Model of HLA-B27-Associated Human Disorders,”Cell63:1099-1112, 1990.
Harlan et al., “In Vivo Models of Leukocyte Adherence to Endothelium,” inAdhesion: Its Role in Inflammatory Disease, Harlan et al. (eds.), W.H. Freeman and Co., New York, 1992, p. 117-150.
Hausen et al., “Viral Serine Proteinase Inhibitor (Serp-1) Effectively Decreases the Incidence of Graft Vasculopathy in Heterotopic Heart Allografts,”Transplantation72:364-368, 2001.
Häyry et al., “Chronic Allograft Rejection,”Transplantation Proc. 28;2337-2338, 1996.
Herzum et al., “Coxsackievirus B3 Infection Leads to Cell Death of Cardiac Myocytes,”J. Mol. Cell Cardiol. 26:907-913, 1994.
Hickey et al., “T-Lymphocyte Entry Into the Central Nervous System,”J. Neurosci. Res. 28:254-260, 1991.
Hill et al., “Soluble Complement Receptor Type 1 Ameliorates the Local and Remote Organ Injury After Intestinal Ischemia-Reperfusion in the Rat,”J. Immunol. 149:1723-1728, 1992.
Howie and Helyer, “The Immunology and Pathology of NZB Mice,”Adv. Immunol. 198:215-266, 1968.
Huber and Pfaeffle, “Differential Th1and Th2Cell Responses in Male and Female BALB/c Mice Infected with Coxsackievirus Group B Type 3,”J. Virology68:5126-5132, 1994.
Jiang and Kanost, “Characterization and Functional Analysis of 12 Naturally Occurring Reactive Site Variants of Serpin-1 fromManduca Sexta,”J. Biol. Chem. 272:1082-1087, 1997.
Jiang et al., “Induction of Indefinite Cardiac Allograft Survival Correlates with Toll-Like Receptor 2 and 4 Downregulation after Serine Protease Inhibitor-1 (SERP-1) Treatment,”Transplantation84:1158-1167, 2007.
Johnstone et al., “Effects of Intraoperative Radiotherapy on Vascular Grafts in a Canine Model,”Int. J. Radiat. Oncol. Biol. Phys. 29:1015-1025, 1994.
Kasahara et al., “Autoimmune Myocarditis Induced in Mice by Cardiac C-Protein- Cloning of Complementary DNA Encoding Murine C
Lucas Alexandra
McFadden D. Grant
Zhong Z. Robert
Bieker-Brady Kristina
Clark & Elbing LLP
Ouspenski Ilia
Viron Therapeutics Inc.
LandOfFree
Method for treating transplant rejection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating transplant rejection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating transplant rejection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2754416